Ten Challenges for Systems Medicine by Enrico Capobianco
Systems Medicine (Auffray et al., 2009, 2010) 
emphasizes the role of systems  biology 
in medical/clinical applications. With the 
advent of new technologies, the “omics” 
explosion (i.e., next generation  sequencing) 
and the induced changes from data-poor 
to data-rich applications (for instance 
related to high-content imaging, physiol-
ogy, and  structural biology) have estab-
lished the necessity of a systems approach 
(Noble, 2008) not to be caught in the data 
deluge. The accumulation and variety of 
high-throughput evidences and studies 
have generated hypothesis-driven models 
and validations at a previously inconceiv-
able scale. Correspondingly, the assembly of 
models tackling all the implied complexities 
suggests challenges for which no standard 
(e.g., specified according to assumptions) 
inference approaches currently exist. In 
response to such problems and uncertain-
ties, both data-driven intensive applications 
and model-free or agnostic (non-paramet-
ric) inferences are re-defining bioinformat-
ics/statistics pipelines and network model 
architectures. Computational tools will be 
designed to satisfy criteria of: (1) Efficiency in 
processing, mining, and analyzing sequenc-
ing data; in particular, parallel architectures 
and high performance computing will be 
necessary to address the current data vol-
umes and complexities; (2) Flexibility in 
synergizing the “omics” fields with clinical, 
biological, and environmental informa-
tion whose integrative nature will require 
network-centric knowledge representation 
systems (Pawson and Linding, 2008; Zanzoni 
et al., 2008; Barabasi et al., 2011) will be very 
important; (3) Accuracy in data post-process-
ing by exploiting model checking through 
robust feature selection and accurate output 
annotation, including clinical samples and 
patients’ follow up information.
The tasks required to satisfy such cri-
teria are highly specific and technical, but 
show interrelationships that lead to systems 
approaches. From one hand, the compo-
nents that need to be considered in such 
systems have heterogeneous features due 
to sample diversity acquired at data-poor 
(patients) and data-rich (cellular, imag-
ing) resolutions, and require normaliza-
tion to exploit complementary evidences 
(experimental, clinical, epidemiological, 
computational, simulation-based) and 
measurements (quantitative, environmen-
tal, perturbation-based). From another 
hand, a consensus concerning data col-
lection and annotation is needed for 
comparative evaluations and assessment 
of data consistencies among studies and 
experiments.
Systems medicine represents a mosaic of 
distinct and interconnected micro-systems 
allowing to infer the macro-systems dynam-
ics and produce elements of synthesis such 
as signatures (Hood and Friend, 2011; Sung 
et al., 2012) and profiles originated by a 
variety of information sources and conse-
quently characterized. For instance, disease 
networks have been discussed by Barabasi 
et al. (2011), while pathway analysis beyond 
“canonical pathways” (Califano et al., 2012) 
and conceived for monitoring and assess-
ing the mechanisms of action of drugs by 
the identification of targets and biomarkers, 
could involve multiple differential condi-
tions to evaluate responses at system’s level 
or at global network scale (protein–protein 
interaction, gene regulatory, microRNA-tar-
get etc.), including deviation from equilib-
rium and/or stability. In response to crucial 
bottlenecks in Systems Medicine, our con-
tribution aims to point out 10 challenges that 
are going to characterize the field, and for 
which Figure 1 provides an ensemble view.
SHIFT OF MEDICAL PARADIGMS – HOw 
DOES A SySTEMS’ APPROACH ALLOw 
TRAnSLATIOn TO EFFECTIvE 
PREvEnTIvE & PERSOnALIzED 
MEDICInE?
Cellular systems are globally organized 
entities consisting of interdependent com-
ponents that contribute to the overall 
functionality and stability, and generate 
information from diversity, variation, and 
complexity achievable only synergistically, 
adaptively, and dynamically. Because of the 
combined interactions and effects between 
constituent entities, such systems embed 
prediction power available to discovery 
(target or biomarker identification) as well 
as inference (clustering and classification) 
in relation to pathological states of diseases, 
diagnostic or prognostic analysis, and pre-
ventive assessment (e.g., risk evaluation). 
The latter would prove the confluence of the 
system’s predictive power to patient-specific 
profiling (see Hood et al., 2012).
CLInICAL PHEnOTyPES – HOw 
InTEGRATIvE COMPuTATIOnAL 
MODELS RE-DEFInE THEM?
New forms of multiplexed profiling will 
play a crucial role for representing and clas-
sifying phenotypic heterogeneity. They will 
address especially one of the current bottle-
neck in an attempt to make it a driving force: 
spatiotemporal high-dimensional profiles. 
Currently time and space dimensions are 
often poorly understood and overlooked in 
data modeling, with a loss of information. 
First, once analyzed in reduced dimensions 
and complexity they could be dynamically 
modeled at multiple scales (omics, clinics, 
imaging, computational) fused together. 
Second, their features (distributions, cor-
relations, etc.) could be inferred by stochas-
tic methods designed to deconvolute simply 
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correlative or noisy patterns from causative 
information in time series. Stochastic sys-
tems allow for data-driven inference based 
on separation of signal from noise, and a 
more accurate assessment on the informa-
tive content of signals improves the defi-
nition and clinical impact of phenotype 
characteristics.
BIOMARKER IDEnTIFICATIOn – ARE 
BIOMARKER SySTEMS uSEFuL TO 
REPRESEnT AnD InTERPRET COMPLEx 
COMBInATORIAL THERAPIES?
Biomarker specificity induces differentia-
tion that is only apparently contrasted at 
systems’ level. Substantial advantages with 
regard to individualized solutions related 
to tissue-specific studies and more effec-
tive diagnosis and therapy are emphasized 
by systems’ integrative aspects based on 
biomarker associations and dependencies 
that lead to combinatorial approaches. 
Biomarker networks may account for such 
complex observed and hidden relationships 
between genes and proteins explaining the 
combined and synergistic effects appear-
ing at (sub-)modular scales. Consequently, 
panel biomarker studies may provide valu-
able functional inference and annotation 
quality to characterize both early diagno-
sis and response to treatment studies, thus 
justifying deviation from the commonly 
accepted biomarker models.
nETwORK AnALySIS – wHAT IS THE 
ROLE OF nETwORKS In DISEASE 
PROCESSInG, AnD THEIR POTEnTIAL 
FOR ELuCIDATInG MuLTISCALE/
MuLTILEvEL InFEREnCE?
Networks represent powerful flexible infer-
ence tools able to decipher very complex 
relationships between variables. In particu-
lar, when differential analysis (Ideker and 
Krogan, 2012) is performed to set compar-
isons between normal and disease states, 
or assess variation between disease states, 
measuring, and evaluating the changes, from 
global topological properties and modular-
ity configurations to local intensity of net-
work links, can establish the significance of 
such variation before conducting thorough 
validation. Variation can be accounted at 
topological level by the definition of metrics, 
based on vertex–vertex dependent distances 
or module-centric entropies, by the proper-
ties of modules (reduced dimensionality and 
complexity, specialization by tissue or cell 
type, etc.) that simplify inference, and by the 
consideration of time and space dynamics 
of disease processes.
InTEGRATIOn – wHAT TyPE OF 
InTEGRATIOn BEST SuITS SySTEMS 
MEDICInE nEEDS?
Integration allows to bypass the problem of 
sparsity of information due to partial or total 
lack of specific annotation in public reposito-
ries and biobanks. Part of the problems come 
from the need of associating heterogeneous 
entities retrieved from different sources: such 
multiple evidences potentially increase the 
overall system’s prediction power, but also 
propagate uncertainty of each source (exper-
imental, clinical, etc.) to levels that might 
prevent from consistent statistical analysis. 
A first solution is finding normalizing and 
re-scaling transforms that allow the data 
diversity to be cast within a model frame-
work. This way the source heterogeneity 
effects would be neutralized. A further step 
involves the control of the system’s redun-
dancy in light of the degree of dependence of 
the integrated information. This way spuri-
ous and noisy correlations in data would be 
mitigated. These two actions would lead to a 
parsimonious normalized model with which 
to compute possible inferences.
vALIDATIOn – wHAT IS THE 
ASSOCIATIOn BETwEEn 
COMPuTATIOnALLy AnD CLInICALLy 
vALIDATED EvIDEnCES?
While clinical validation is always consid-
ered necessary, computational validation is 
often overlooked. Data-based results need 
to be tested for assessing the presence of real 
structural features instead of associations 
due just to chance. Statistical techniques and 
model checking strategies may determine sig-
nificance in such regards. A more extended 
concept of validation involves replication 
strategies (montecarlo, bootstrap, bagging, 
etc.) and methodologies aimed to build unbi-
ased “null models” that adapt to the nature 
of the data (see for interactome data Marras 
et al., 2010). Then, once benchmarks for com-
plex data structures are found, computational 
validation requires testing over independent 
data sets to establish “consistency” of results.
unCERTAInTy ASSESSMEnT – HOw 
RELIABLE IS InFEREnCE wHEn An 
InTEGRATIvE DynAMIC BIO-SySTEM IS 
COnSIDERED?
The confidence with which we assess the 
presence of informative dynamics instead of 
noise, or establish the presence of structural 
Figure 1 | Links between Challenges. A modularization of the Bioinformatics Infrastructure embedding 
integratively and significantly validated inferences will lead to a Systems Medicine Paradigm Shift.
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just started to be studied (Goh et al., 2007; 
Jia et al., 2009). At systems’ level the power 
of network screening approaches refers to 
identifying phenotype varieties linked to 
the prediction of specific disease forms, and 
augmenting the druggable space through 
novel targets (Schadt et al., 2009).
BIOInFORMATICS InFRASTRuCTuRE – 
HOw TO EFFECTIvELy, EFFICIEnTLy AnD 
ACCuRATELy SuPPORT AnD PERFORM 
THE TRAnSLATIOnAL EFFORTS AHEAD?
By a wider access to a variety of information 
layers, an increased statistical power will be 
available from samples and their biological 
and clinical annotation for computational 
exploitation. An up-to-date bioinformatics 
environment would need to establish the 
fusion of all validated clinical, experimental, 
and computational evidences. In turn, mul-
tilevel knowledge management approaches 
(Szalma et al., 2010) will be required to 
overcome the infrastructural bottlenecks. 
In general, storage costs can hardly keep 
the pace of data-intensive bio-applications 
without technological developments. In 
particular, while high performance comput-
ing must address critical aspects involving 
replicated generations, parallel computa-
tions, and efficient storage, both analytical 
and algorithmic solutions will deal with 
complex inference tasks at multiple scales 
and together contribute to implement inte-
grative research.
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complexity instead of artifacts depends on 
factors such as the informative content of 
data, the model identifiability, the signifi-
cance of results. Usually, sampling effects, 
errors, and experimental biases affect the 
accuracy of measurements at the experi-
mental level. Limiting the effects of such 
aberrations involves the use of analysis too, 
through sampling and resampling tech-
niques, intervention strategies for improv-
ing its robustness, and control of system’s 
stability. However, the role of noise and com-
plexity must be deciphered and not simply 
neutralized or bypassed as they contribute to 
establish inference methods based on model 
robustness and regularization properties.
CO-MORBIDITy – wHAT SySTEMS 
RE-MODuLARIzATIOn IS ExPECTED 
AFTER SHOCKS?
The equilibrium-disequilibrium dynam-
ics involved in co-morbidity contexts 
(Bousquet et al., 2011) suggest that the 
effects of perturbing factors must be con-
sidered more carefully. For instance, when 
acute phases affect one or more pathologi-
cal states, the co-morbidity map changes in 
two aspects: the role of each component in 
terms of relative relevance, and the inter-
action strength between components. The 
relevance of each component is determined 
in relation to the dominance exerted over 
the pathological patterns, and thus orient-
ing the therapeutic decisions. The interac-
tion strengths can be measured in terms of 
causative or propagation dynamics, and in 
relation to equilibrium versus non-equi-
librium conditions. At system’s scale, a re-
modularization involves the adaptive power 
of each constituent component in response 
to perturbation dynamics.
DRuG DEvELOPMEnT/SCREEnInG – 
DRuG-TARGET AnD DRuG–DRuG 
nETwORKS: wHAT FuTuRE FOR THEM?
Drugs directed to targets can be limited 
in their overall efficacy by the presence of 
network redundancies (off-targeted effects) 
and robust features (cross-talks) whose 
compensatory actions contrast or neu-
tralize the target-related activities (Croft 
et al., 2011). Systems-oriented drug design 
improve our general understanding of the 
mechanisms of action, particularly when 
dealing with drug combinations and multi-
target agents whose complex dynamics have 
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